Novavax
9920 Belward Campus Drive
Rockville
Maryland
20850
United States
Tel: 240-268-2000
Website: http://www.novavax.com/
461 articles with Novavax
-
Shares of Maryland-based Novavax are down 66 percent in morning trading after the company announced its respiratory syncytial virus (RSV) vaccine called ResVax failed to hit its primary endpoint in a Phase III trial.
-
With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing investors about pipeline advances. BioSpace snagged some of the interesting news bits to come out of the conference from Wednesday.
-
Novavax Announces Positive Phase 2 NanoFlu Results in Older Adults
1/3/2019
Novavax, Inc. (NASDAQ: NVAX) today announced top-line results of its Phase 2 clinical trial of NanoFlu™.
-
Novavax to Highlight RSV Program Data at Two Upcoming Meetings
10/2/2018
Novavax, Inc. today announced that its representatives will share data from its RSV F vaccine program via oral and poster presentations at IDWeek 2018 in San Francisco, California, taking place October 3-7 and at the 11th International Respiratory Syncytial Virus Symposium in Asheville, North Carolina, taking place October 31-November 4.
-
Here's Five Vaccines to Keep Your Eye on
8/15/2018
On a dollar-for-dollar basis, vaccines have probably had a greater positive effect on global health than any other medical advancement, except possibly antibiotics. Yet as a whole, it’s an area that pharma companies tend to not spend a lot of resources on. But there are still many companies that ... -
Novavax Reports Second Quarter 2018 Financial Results
8/8/2018
Novavax Delivers on Key Milestones Supporting its 2018 Objectives
-
Novavax to Host Conference Call to Discuss Second Quarter Financial Results on August 8, 2018
8/1/2018
Novavax, Inc. announced it will report its second quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, August 8, 2018.
-
The biopharma industry generally views vaccines to be low-margin investments. From a public health perspective, however, vaccines can be one of the best investment dollars.
-
New England Journal of Medicine Publishes Novavax’ NanoFlu Clinical Trial Data
6/13/2018
NanoFlu Phase 1/2 trial data published in a peer-reviewed letter to the editor in The New England Journal of Medicine
-
The Bill and Melinda Gates Foundation has spun off a biotech company called The Bill & Melinda Gates Medical Research Institute (MRI) located in Boston. Although it found its temporary space in Cambridge, Massachusetts in January, it “officially” launched Thursday at the BIO International Convent...
-
Public health officials and scientists have had concerns about how long Ebola vaccines’ protection lasts. A new study shows that one of those vaccines confers at least two years of protection.
-
If you had a crystal ball, you probably would have invested in Berkshire Hathaway in 1964, or Apple in the 1980s.
-
A look at why investors should stock up on Amgen, Celldex Therapeutics, and Novavax soon.
-
Novavax Continues Phase III Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase I/II Trial of the NanoFlu Vaccine
12/19/2017
Novavax also provided an update on its nanoparticle influenza vaccine candidate with proprietary Matrix-M adjuvant.
-
As 2018 winds down, it's not over for some biopharma companies.
-
These great biotech stocks to buy for the holidays come in all sizes -- small-cap, mid-cap, and large-cap.
-
This biotech has had a year where its stock had grown 20 percent and roller-coastered down 20 percent, several times.
-
Novavax Reports Third Quarter 2017 Financial Results
11/8/2017
Novavax reported a net loss of $44.6 million, or $0.15 per share, for the third quarter of 2017, compared to a net loss of $66.3 million, or $0.24 per share, for the third quarter of 2016.
-
Novavax to Host Conference Call to Discuss Third Quarter 2017 Financial Results on November 7, 2017
11/1/2017
The company will report its third quarter financial and operating results following the close of U.S. financial markets.
-
Novavax announced today that Barclay A. “Buck” Phillips has submitted his resignation as Senior Vice President, CFO and Treasurer.